Regresar

Foto de Basile J.N.

Basile J.N.

397

Coauthors

10

Documentos

Volumen de publicaciones por año

Cargando gráfico

Año de publicación	Num. Publicaciones
2018	1
2019	2
2020	3
2021	2
2022	2

Publicaciones por áreas de conocimiento

Cargando gráfico

Área de conocimiento	Num. Publicaciones
Medicina interna	8
Diabetes	7
Medicamento	3
Enfermedad cardiovascular	2
Cognición	2
Neurología	1

Publicaciones por áreas temáticas

Cargando gráfico

Área temática	Num. Publicaciones
Enfermedades	9
Farmacología y terapéutica	8
Medicina y salud	4
Fisiología humana	3
Problemas sociales y servicios a grupos	1
Ginecología, obstetricia, pediatría, geriatría	1
Medicina forense; incidencia de enfermedades	1

Principales fuentes de datos

Origen	Num. Publicaciones
Scopus	10
Google Scholar	9
RRAAE	0

Cargando gráfico

Coautores destacados por número de publicaciones

Coautor	Num. Publicaciones
Leiter L.A.	10
Pogosova N.	10
PATRICIO LOPEZ -JARAMILLO	10
Rydén L.E.	10
Raubenheimer P.J.	10
Probstfield J.L.	10
Gerstein H.C.	9
Sheu W.H.H.	9
Shaw J.E.	9
Lakshmanan M.	9

Cargando gráfico

Top Keywords

Cargando gráfico

Publicaciones del autor

Dulaglutide and incident atrial fibrillation or flutter in patients with type 2 diabetes: A post hoc analysis from the REWIND randomized trial

Abstract: Aim: To assess the occurrence of atrial fibrillation or atrial flutter (atrial arrhythmias [AA]) in

Palabras claves:

Atrial Fibrillation, atrial flutter, dulaglutide, glucagon-like peptide-1 receptor agonists, Type 2 Diabetes

Avezum A.J., Basile J.N., C. Gerstein H., Conget I., Cushman W.C., Dagenais G.R., Hoover A., Jansky P., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Sheu W.H.H., Temelkova-Kurktschiev T.

Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial

Abstract: Background: Diabetes is a major risk factor for erectile dysfunction, however, the effect of GLP-1 r

Palabras claves:

Bajaj H.S., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Franek E., Gerstein H.C., Hanefeld M., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Rao-Melacini P., Raubenheimer P.J., Rydén L.E., Shaw J.E., Sheu W.H.H., Xavier D.

Similar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin

Abstract: Objective : Recent European Guidelines for Diabetes, Pbkp_rediabetes and Cardiovascular Diseases int

Palabras claves:

Cardiovascular disease, GLP-1-based therapy, Metformin, Morbidity, Mortality

Avezum A.J., Basile J.N., Colhoun H.M., Cushman W.C., Dagenais G.R., DIaz R., Dyal L., Ferrannini G., Gerstein H.C., Jansky P., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Mellbin L., Pais P., PATRICIO LOPEZ -JARAMILLO, PīrCrossed D Sign gs V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H.

Total cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis

Abstract: Background: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) double

Palabras claves:

Cardiovascular disease, Glucagon like peptide-1 receptor agonists, Type 2 Diabetes

Atisso C.M., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Dyal L., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Munoz E.G.C., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T.

Novel Indices of Cognitive Impairment and Incident Cardiovascular Outcomes in the REWIND Trial

Abstract: Context: Low cognitive scores are risk factors for cardiovascular outcomes. Whether this relationshi

Palabras claves:

cardiovascular events, cognitive impairment, Composite outcome, death, Geometric mean, MACE, risk factor, stroke

Angelyn Bethel M., Basile J.N., Cardona-Munoz E.G., Conget I., Cukierman-Yaffee T., Dagenais G.R., Franek E., Gerstein H.C., Hall S., Hâncu N., Jansky P., Lakshmanan M., Lanas F., Leiter L.A., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Ramasundarahettige C., Rao-Melacini P., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu H.H., Temelkova-Kurktschiev T.